These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38140219)

  • 1. The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.
    Jiang H; Jin P; Guo X; Zhu J; Wang X; Wan P; Wan J; Liu J; Li J; Zhu F
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
    Jin PF; Guo XL; Gou JB; Hou LH; Song ZZ; Zhu T; Pan HX; Zhu JH; Shi FJ; Du P; Huang HT; Liu JX; Zheng H; Wang X; Chen Y; Wan P; Wu SP; Wang XW; Xu XY; Yan FR; Li JX; Chen W; Zhu FC
    Lancet Reg Health West Pac; 2023 Jun; 38():100829. PubMed ID: 37360864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Li J; Hou L; Guo X; Jin P; Wu S; Zhu J; Pan H; Wang X; Song Z; Wan J; Cui L; Li J; Chen Y; Wang X; Jin L; Liu J; Shi F; Xu X; Zhu T; Chen W; Zhu F
    Nat Med; 2022 Feb; 28(2):401-409. PubMed ID: 35087233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
    Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.
    Jin L; Tang R; Wu S; Guo X; Huang H; Hou L; Chen X; Zhu T; Gou J; Zhong J; Pan H; Cui L; Chen Y; Xia X; Feng J; Wang X; Zhao Q; Xu X; Li Z; Zhang X; Chen W; Li J; Zhu F
    Emerg Microbes Infect; 2023 Dec; 12(1):2155251. PubMed ID: 36503413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
    Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
    Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults.
    Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R
    J Infect Dis; 2023 Nov; 228(9):1253-1262. PubMed ID: 37439701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
    Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
    Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
    Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
    Zhu F; Jin P; Zhu T; Wang W; Ye H; Pan H; Hou L; Li J; Wang X; Wu S; Wang Y; Gou J; Huang H; Wu H; Wang X; Chen W
    Clin Infect Dis; 2022 Aug; 75(1):e783-e791. PubMed ID: 34551104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3-9-month intervals following two-dose inactivated vaccine (CoronaVac).
    Liao Y; Chen Y; Chen B; Liang Z; Hu X; Xing B; Yang J; Zheng Q; Hua Q; Yan C; Lv H
    Front Immunol; 2022; 13():1017590. PubMed ID: 36426361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine.
    Mahasirimongkol S; Khunphon A; Kwangsukstid O; Sapsutthipas S; Wichaidit M; Rojanawiwat A; Wichuckchinda N; Puangtubtim W; Pimpapai W; Soonthorncharttrawat S; Wanitchang A; Jongkaewwattana A; Srisutthisamphan K; Phainupong D; Thawong N; Piboonsiri P; Sawaengdee W; Somsaard T; Ritthitham K; Chumpol S; Pinyosukhee N; Wichajarn R; Dhepakson P; Iamsirithaworn S; Phumiamorn S
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.
    Huang T; Zhang S; Dai DF; Wang BS; Zhuang L; Huang HT; Wang ZF; Zhao JS; Li QP; Wu SP; Wang X; Zhang WD; Zhao ZH; Li H; Zhang YP; Yang XL; Jiang XY; Gou JB; Hou LH; Gao LD; Feng ZC
    Lancet Respir Med; 2023 Aug; 11(8):698-708. PubMed ID: 37209700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
    Tang R; Zheng H; Wang BS; Gou JB; Guo XL; Chen XQ; Chen Y; Wu SP; Zhong J; Pan HX; Zhu JH; Xu XY; Shi FJ; Li ZP; Liu JX; Zhang XY; Cui LB; Song ZZ; Hou LH; Zhu FC; Li JX;
    Lancet Respir Med; 2023 Jul; 11(7):613-623. PubMed ID: 36898400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
    Li JX; Wu SP; Guo XL; Tang R; Huang BY; Chen XQ; Chen Y; Hou LH; Liu JX; Zhong J; Pan HX; Shi FJ; Xu XY; Li ZP; Zhang XY; Cui LB; Tan WJ; Chen W; Zhu FC;
    Lancet Respir Med; 2022 Aug; 10(8):739-748. PubMed ID: 35605625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.